Safety and Immunogenicity of Recombinant Pichia Pastoris AMA1-DiCo Candidate Malaria Vaccine With GLA-SE and Alhydrogel ® as Adjuvant in Healthy Malaria Non-Exposed European and Malaria Exposed African Adults

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

66 participants

Study Classification

INTERVENTIONAL

Study Start Date

2014-01-31

Study Completion Date

2015-07-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The primary objective is to evaluate the safety of 3 doses given at D0, W4, and W26 of 50 µg dosage of AMA1-DiCo adjuvanted either with GLA-SE or Alhydrogel® in healthy European adults not previously exposed to the parasite P.falciparum and in healthy African adults exposed to the parasite. The safety and the tolerability of the vaccine will be assessed on the rate of solicited and unsolicited events/reactions. The safety profile will include local and systemic reactions/events as well as the biological safety, based on a clinically significant change of the baseline value of the main biological criteria.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Safety And Immunogenicity Of Novel Candidate Blood-Stage Malaria Vaccine P27A : Phase Ia/Ib

NCT01949909

Malaria

COMPLETED PHASE1

Initial Study of Malaria Vaccine Pfs25-EPA/Alhydrogel(Registered Trademark)

NCT01434381

Malaria

COMPLETED PHASE1

Trial to Evaluate the Safety and Immunogenicity of a Placental Malaria Vaccine Candidate (PRIMVAC ) in Healthy Adults

NCT02658253

Malaria

COMPLETED PHASE1

Malaria Vaccine for Children in Mali

NCT00740090

Malaria Malaria Infection

COMPLETED PHASE1

Experimental PfSPZ Vaccine in Adults Without Malaria

NCT01441167

Malaria Prevention and Control Acquired Immunity

COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The project aims are :

-To evaluate the safety of 50 µg AMA1-DiCo malaria vaccine candidate with GLA-SE and Alhydrogel® as adjuvant, in healthy European adults not previously exposed to the parasite Plasmodium falciparum and in healthy African adults exposed to the parasite.

T-o assess the humoral immune response to the vaccine antigens by measuring the level of IgG in all volunteers.

To assess the cellular immune response by measuring the T cell cytokines IL-5 and IFNγ production following in vitro stimulation with the vaccine antigens in all volunteers.

Design :

This trial is a staggered Phase Ia/Ib, Randomised, Double-blind, Multi-center Centre trial.

Two different adjuvants will be assessed, Alhydrogel® and GLA-SE. One dosage of 50 µg/3 injections of AMA1-DiCo will be evaluated for each adjuvant.

Sixty six (66) healthy volunteers will be included into the 2 following cohorts (A and B):

Cohort A: 30 Non-exposed European Volunteers (France) Cohort B: 36 Malaria Exposed African Volunteers (Burkina Faso)

The non-exposed European volunteers (cohort A) will be randomised in a 1:1 ratio into two groups of 15 volunteers per group.

The malaria exposed African volunteers (cohort B) will be randomised in a 1:1 ratio, into two groups of 18 volunteers per group.

European Volunteers: Cohort A (30):

Group A1 (15): 50µg AMA1-DiCo + Alhydrogel® Group A2 (15): 50 µg AMA1-DiCo+ GLA-SE

African Volunteers Cohort B (36) :

Group B1 (18): 50 µg AMA1-DiCo + GLA-SE Group B2 (18): Placebo (isotonic saline solution)

In order to start recruitment in cohort B (Africa), the safety will be evaluated on the data of all European volunteers until Day 7 after 1st immunisation of the last European volunteer Data will be presented to an Independent Data safety Monitoring Board (DSMB) that will be appointed for this trial

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Malaria, Falciparum

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

AMA1-DiCo + Alhydrogel

AMA1-DiCo: 50µg Alhydrogel® : 0.85 mg Al3+ per dose Route : Intramuscular Vaccination schedule : Do, W4, W26

Group Type EXPERIMENTAL

Group A1 : 50µg AMA1-DiCo + Alhydrogel

Intervention Type BIOLOGICAL

AMA1-DiCo+ GLA-SE

Group A2 (15) : European volunteer : AMA1-DiCo + GLA-SE

AMA1-DiCo: 50µg

GLA-SE 2.5 µg GLA per dose

Route : Intramuscular Vaccination schedule : Do, W4, W26

Group Type EXPERIMENTAL

Group A2 : 50 µg AMA1-DiCo+ GLA-SE

Intervention Type BIOLOGICAL

AMA1-DiCo + GLA-SE

Group B1 (18) : African volunteer : AMA1-DiCo + GLA-SE

AMA1-DiCo: 50µg

GLA-SE 2.5 µg GLA per dose

Route : Intramuscular Vaccination schedule : Do, W4, W26

Group Type EXPERIMENTAL

Group A2 : 50 µg AMA1-DiCo+ GLA-SE

Intervention Type BIOLOGICAL

Placebo

Group B2 (18) : African volunteer : Placebo

Placebo : isotonic saline solution

Route : Intramuscular Vaccination schedule : Do, W4, W26

Group Type PLACEBO_COMPARATOR

Group B2 : Placebo

Intervention Type BIOLOGICAL

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Group A1 : 50µg AMA1-DiCo + Alhydrogel

Intervention Type BIOLOGICAL

Group A2 : 50 µg AMA1-DiCo+ GLA-SE

Intervention Type BIOLOGICAL

Group B2 : Placebo

Intervention Type BIOLOGICAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Age \> 20 and \< 45 years healthy female and male
2. General good health based on history and clinical examination.
3. Written informed consent obtained before any trial procedure.
4. Female and male volunteers practicing contraception before and up to four (4) weeks after the third vaccination.
5. Available to participate in follow-up for the duration of trial.
6. Reachable by phone during the whole trial period.
7. Volunteers should be affiliated to a social security regimen

Exclusion Criteria

1. Positive pregnancy test
2. Active breast feeding
3. Previous participation in any malaria vaccine trial
4. History of blood transfusion within the last 6 months
5. Symptoms, physical signs or laboratory values suggestive of systemic disorders, including renal, hepatic, cardiovascular, pulmonary, skin, immunodeficiency, psychiatric and other conditions, which could interfere with the interpretation of the trial results or compromise the health of the volunteers.
6. Any clinically significant laboratory abnormalities on screened blood samples outside the normal range, as defined at the clinical trial site.
7. Enrolment in any other clinical trial during the whole trial period
8. Intake of chronic medication, especially immunosuppressive agents (steroids, immunomodulating or immunosuppressive drugs) during the thirteen weeks preceding the screening visit or during the trial period except topical steroid use including intranasal.
9. Any confirmed or suspected immunosuppressive or immunodeficiency condition during the whole trial period
10. Volunteers unable to be closely followed for social, geographic or psychological reasons.
11. Previous history of drug or alcohol abuse interfering with normal social function during a period of one year prior to enrolment in the trial.
12. History of anaphylaxis or Known severe hypersensitivity to any of the vaccine components (adjuvant or antigen or excipient)
13. Vaccination or gamma globulin: 4 weeks prior and after each vaccination if a vaccination is necessary during this period, the volunteer will be withdrawn from the study.
14. Positive HIV, HBV (Ag HBS) and HCV tests.
15. History of malaria or travel in malaria endemic areas within the past twenty-six weeks.
16. Positive serology for malaria antigen PfAMA-1
17. Intention to travel to malaria endemic countries during the trial period.

\-

Minimum Eligible Age

20 Years

Maximum Eligible Age

45 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Odile Launay, Professor

Role: PRINCIPAL_INVESTIGATOR

CIC BT505 Cochin Pasteur Groupe Hospitalier Cochin Broca Hotel Dieu. Bâtiment Lavoisier 27, rue du Faubourg Saint-Jacques 75679 PARIS Cedex 14, France [email protected]

Sodiomon Sirima, Doctor

Role: PRINCIPAL_INVESTIGATOR

Centre National de Recherche et de Formation sur le Paludisme (CNRFP 01 BP 2208 Ouagadougou 01 1487, Avenue KumdaYonré, Burkina Faso [email protected]